Company / Financials
REGENEREX PHARMA, INC. Financials
FY2019-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.8K
FY2020 · -31.9% YoY
Net Income
-$353.8K
FY2020 · -417.0% YoY
Profit Margin
-19929.7%
FY2020 · net income / revenue
ROE
-
FY2020 · return on equity
Total Assets
$259.2K
FY2020
Total Debt
-
FY2020
Equity
-$481.3K
FY2020
ROA
-136.5%
FY2020 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -6.05 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.8K-31.9% YoYNet Income HistoryProfit after all expenses and taxes-$353.8K-417.0% YoYGross Profit HistoryRevenue minus cost of goods sold-$244.9K-27434.5% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$1.1K-34.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$43.4K+43.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$43.4K-28.9% YoYInterest Expense HistoryCost of borrowing and debt obligations$42.9K+49.7% YoYShares Outstanding HistoryWeighted average diluted shares outstanding127.1M0.0% YoYTotal Assets HistoryTotal value of all assets owned$259.2K+145.4% YoYShareholders' Equity HistoryTotal assets minus total liabilities-$481.3K-30.2% YoY